301 related articles for article (PubMed ID: 30005773)
21. Breast-conserving therapy for triple-negative breast cancer.
Gangi A; Chung A; Mirocha J; Liou DZ; Leong T; Giuliano AE
JAMA Surg; 2014 Mar; 149(3):252-8. PubMed ID: 24382582
[TBL] [Abstract][Full Text] [Related]
22. Biology and Management of Patients With Triple-Negative Breast Cancer.
Sharma P
Oncologist; 2016 Sep; 21(9):1050-62. PubMed ID: 27401886
[TBL] [Abstract][Full Text] [Related]
23. Role of Carboplatin in the Treatment of Triple Negative Early- Stage Breast Cancer.
Valsecchi ME; Kimmey G; Bir A; Silbermins D
Rev Recent Clin Trials; 2015; 10(2):101-10. PubMed ID: 26104428
[TBL] [Abstract][Full Text] [Related]
24. Should triple-negative breast cancer (TNBC) subtype affect local-regional therapy decision making?
Moran MS
Am Soc Clin Oncol Educ Book; 2014; ():e32-6. PubMed ID: 24857120
[TBL] [Abstract][Full Text] [Related]
25. Role of TP53 mutations in triple negative and HER2-positive breast cancer treated with neoadjuvant anthracycline/taxane-based chemotherapy.
Darb-Esfahani S; Denkert C; Stenzinger A; Salat C; Sinn B; Schem C; Endris V; Klare P; Schmitt W; Blohmer JU; Weichert W; Möbs M; Tesch H; Kümmel S; Sinn P; Jackisch C; Dietel M; Reimer T; Loi S; Untch M; von Minckwitz G; Nekljudova V; Loibl S
Oncotarget; 2016 Oct; 7(42):67686-67698. PubMed ID: 27611952
[TBL] [Abstract][Full Text] [Related]
26. The evolving role of immune checkpoint inhibitors in the treatment of triple-negative breast cancer.
Steiner M; Tan AR
Clin Adv Hematol Oncol; 2021 May; 19(5):305-315. PubMed ID: 33989278
[TBL] [Abstract][Full Text] [Related]
27. Matrix-producing Carcinoma as an Aggressive Triple-negative Breast Cancer: Clinicopathological Features and Response to Neoadjuvant Chemotherapy.
Shimada K; Ishikawa T; Yamada A; Sugae S; Narui K; Shimizu D; Chishima T; Endo I
Anticancer Res; 2019 Jul; 39(7):3863-3869. PubMed ID: 31262914
[TBL] [Abstract][Full Text] [Related]
28. Current strategy for triple-negative breast cancer: appropriate combination of surgery, radiation, and chemotherapy.
Yagata H; Kajiura Y; Yamauchi H
Breast Cancer; 2011 Jul; 18(3):165-73. PubMed ID: 21290263
[TBL] [Abstract][Full Text] [Related]
29. Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial.
von Minckwitz G; Schneeweiss A; Loibl S; Salat C; Denkert C; Rezai M; Blohmer JU; Jackisch C; Paepke S; Gerber B; Zahm DM; Kümmel S; Eidtmann H; Klare P; Huober J; Costa S; Tesch H; Hanusch C; Hilfrich J; Khandan F; Fasching PA; Sinn BV; Engels K; Mehta K; Nekljudova V; Untch M
Lancet Oncol; 2014 Jun; 15(7):747-56. PubMed ID: 24794243
[TBL] [Abstract][Full Text] [Related]
30. Metastatic triple negative breast cancer: Optimizing treatment options, new and emerging targeted therapies.
Khosravi-Shahi P; Cabezón-Gutiérrez L; Custodio-Cabello S
Asia Pac J Clin Oncol; 2018 Feb; 14(1):32-39. PubMed ID: 28815913
[TBL] [Abstract][Full Text] [Related]
31. ¹⁸F-FDG PET/CT for the Early Evaluation of Response to Neoadjuvant Treatment in Triple-Negative Breast Cancer: Influence of the Chemotherapy Regimen.
Groheux D; Biard L; Giacchetti S; Teixeira L; Hindié E; Cuvier C; Vercellino L; Merlet P; de Roquancourt A; de Cremoux P; Resche-Rigon M; Espié M
J Nucl Med; 2016 Apr; 57(4):536-43. PubMed ID: 26697967
[TBL] [Abstract][Full Text] [Related]
32. Triple-Negative Breast Cancers: Systematic Review of the Literature on Molecular and Clinical Features with a Focus on Treatment with Innovative Drugs.
Diana A; Franzese E; Centonze S; Carlino F; Della Corte CM; Ventriglia J; Petrillo A; De Vita F; Alfano R; Ciardiello F; Orditura M
Curr Oncol Rep; 2018 Aug; 20(10):76. PubMed ID: 30128845
[TBL] [Abstract][Full Text] [Related]
33. Triple-negative breast cancer: advancements in characterization and treatment approach.
Hurvitz S; Mead M
Curr Opin Obstet Gynecol; 2016 Feb; 28(1):59-69. PubMed ID: 26694831
[TBL] [Abstract][Full Text] [Related]
34. Neoadjuvant therapy for triple negative and HER2-positive early breast cancer.
Harbeck N; Gluz O
Breast; 2017 Aug; 34 Suppl 1():S99-S103. PubMed ID: 28666920
[TBL] [Abstract][Full Text] [Related]
35. Eight Year Survival Analysis of Patients with Triple Negative Breast Cancer in India.
Chandra D; Suresh P; Sinha R; Azam S; Batra U; Talwar V; Kumar K; Mehta A
Asian Pac J Cancer Prev; 2016; 17(6):2995-9. PubMed ID: 27356724
[TBL] [Abstract][Full Text] [Related]
36. Triple-Negative Breast Cancer in Ghanaian Women: The Korle Bu Teaching Hospital Experience.
Der EM; Gyasi RK; Tettey Y; Edusei L; Bayor MT; Jiagge E; Gyakobo M; Merajver SD; Newman LA
Breast J; 2015; 21(6):627-33. PubMed ID: 26547900
[TBL] [Abstract][Full Text] [Related]
37. Clinical Implications of iNOS Levels in Triple-Negative Breast Cancer Responding to Neoadjuvant Chemotherapy.
Jin Z; Wang W; Jiang N; Zhang L; Li Y; Xu X; Cai S; Wei L; Liu X; Chen G; Zhou Y; Liu C; Li Z; Jin F; Chen B
PLoS One; 2015; 10(7):e0130286. PubMed ID: 26196284
[TBL] [Abstract][Full Text] [Related]
38. Subtyping of triple-negative breast cancer: implications for therapy.
Abramson VG; Lehmann BD; Ballinger TJ; Pietenpol JA
Cancer; 2015 Jan; 121(1):8-16. PubMed ID: 25043972
[TBL] [Abstract][Full Text] [Related]
39. Predictive Value of Tertiary Lymphoid Structures Assessed by High Endothelial Venule Counts in the Neoadjuvant Setting of Triple-Negative Breast Cancer.
Song IH; Heo SH; Bang WS; Park HS; Park IA; Kim YA; Park SY; Roh J; Gong G; Lee HJ
Cancer Res Treat; 2017 Apr; 49(2):399-407. PubMed ID: 27488875
[TBL] [Abstract][Full Text] [Related]
40. HAGE in Triple-Negative Breast Cancer Is a Novel Prognostic, Predictive, and Actionable Biomarker: A Transcriptomic and Protein Expression Analysis.
Abdel-Fatah TM; McArdle SE; Agarwal D; Moseley PM; Green AR; Ball GR; Pockley AG; Ellis IO; Rees RC; Chan SY
Clin Cancer Res; 2016 Feb; 22(4):905-14. PubMed ID: 26240276
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
